Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Irritable Bowel Syndrome I: Introduction01:17

Irritable Bowel Syndrome I: Introduction

780
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
780
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation01:30

Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation

601
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
601
Irritable Bowel Syndrome III: Medical and Nursing Management01:30

Irritable Bowel Syndrome III: Medical and Nursing Management

547
Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
547
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

557
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
557
Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

668
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
668
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

493
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
493

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intensity modulated radiation therapy in prostate cancer-Better survival with higher total dose?

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]·2025
Same author

[Benign prostate syndrome].

Urologie (Heidelberg, Germany)·2025
Same author

Predictive Factors of Transient Urinary Incontinence Following Holmium Laser Enucleation of the Prostate (HoLEP): Single-Center Experience.

Medicina (Kaunas, Lithuania)·2024
Same author

[Case-based presentation of the S2e guideline on the diagnosis and treatment of benign prostatic hyperplasia].

Urologie (Heidelberg, Germany)·2024
Same author

[Minimally invasive treatment of benign prostatic hyperplasia : The German S2e guideline 2023-part 4].

Urologie (Heidelberg, Germany)·2024
Same author

[Surgical treatment options of lower urinary tract symptoms due to benign prostatic obstruction : The German S2e guideline 2023-part 3].

Urologie (Heidelberg, Germany)·2023
Same journal

Der Urologe. Ausg. A·2022
Same journal

Der Urologe. Ausg. A·2022
Same journal

Der Urologe. Ausg. A·2022
Same journal

Der Urologe. Ausg. A·2022
Same journal

Der Urologe. Ausg. A·2022
Same journal

Der Urologe. Ausg. A·2022
See all related articles

Related Experiment Video

Updated: Dec 11, 2025

Urinary Bladder Distention Evoked Visceromotor Responses as a Model for Bladder Pain in Mice
11:46

Urinary Bladder Distention Evoked Visceromotor Responses as a Model for Bladder Pain in Mice

Published on: April 27, 2014

18.2K

[Interstitial cystitis/bladder pain syndrome (IC/BPS)].

Thomas Bschleipfer1

  • 1Klinik für Urologie, Andrologie und Kinderurologie, Interdisziplinäres Kontinenz- und Beckenbodenzentrum Weiden, Zentrum für Interstitielle Zystitis (IC) und Beckenschmerz, Klinikum Weiden/Kliniken Nordoberpfalz AG, Söllnerstraße 16, 92637, Weiden, Deutschland. Th.B@gmx.de.

Der Urologe. Ausg. A
|August 26, 2020
PubMed
Summary
This summary is machine-generated.

Interstitial cystitis/bladder pain syndrome (IC/BPS) is an underdiagnosed orphan disease. Patient classification by symptom severity and type can aid in developing individualized treatment plans for IC/BPS.

Keywords:
Chronic pelvic painDiagnosticsHypersensitive bladderTherapyUrinary bladder

More Related Videos

Treating Low Back Pain in Failed Back Surgery Patients with Multicolumn-lead Spinal Cord Stimulation
04:42

Treating Low Back Pain in Failed Back Surgery Patients with Multicolumn-lead Spinal Cord Stimulation

Published on: June 26, 2018

15.0K
Chronic Post-Ischemia Pain Model for Complex Regional Pain Syndrome Type-I in Rats
07:12

Chronic Post-Ischemia Pain Model for Complex Regional Pain Syndrome Type-I in Rats

Published on: January 21, 2020

8.2K

Related Experiment Videos

Last Updated: Dec 11, 2025

Urinary Bladder Distention Evoked Visceromotor Responses as a Model for Bladder Pain in Mice
11:46

Urinary Bladder Distention Evoked Visceromotor Responses as a Model for Bladder Pain in Mice

Published on: April 27, 2014

18.2K
Treating Low Back Pain in Failed Back Surgery Patients with Multicolumn-lead Spinal Cord Stimulation
04:42

Treating Low Back Pain in Failed Back Surgery Patients with Multicolumn-lead Spinal Cord Stimulation

Published on: June 26, 2018

15.0K
Chronic Post-Ischemia Pain Model for Complex Regional Pain Syndrome Type-I in Rats
07:12

Chronic Post-Ischemia Pain Model for Complex Regional Pain Syndrome Type-I in Rats

Published on: January 21, 2020

8.2K

Area of Science:

  • Urology
  • Pain Management

Background:

  • Interstitial cystitis/bladder pain syndrome (IC/BPS) is a chronic, underdiagnosed bladder condition with unknown causes.
  • IC/BPS presents with diverse symptoms, lacks biomarkers, and is diagnosed by exclusion, posing challenges for clinicians and patients.
  • Current treatments include oral medications, intravesical procedures, and transurethral interventions, with surgery reserved as a last resort due to invasiveness.

Purpose of the Study:

  • To highlight the diagnostic and therapeutic challenges of IC/BPS.
  • To emphasize the need for individualized treatment strategies for IC/BPS patients.
  • To propose patient classification as a method for tailoring IC/BPS therapies.

Main Methods:

  • Review of current understanding and treatment modalities for IC/BPS.
  • Discussion of diagnostic challenges, including symptom variability and lack of biomarkers.
  • Exploration of treatment options from conventional to surgical interventions.

Main Results:

  • IC/BPS diagnosis is often delayed due to its complex nature and exclusion criteria.
  • A wide range of treatments exist, but their effectiveness varies significantly among patients.
  • Surgical interventions carry risks and should be considered cautiously.

Conclusions:

  • Effective management of IC/BPS requires a comprehensive approach.
  • Classifying IC/BPS patients based on symptom profiles can facilitate personalized treatment.
  • Further research into biomarkers and standardized diagnostic criteria is crucial for improving IC/BPS care.